Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 1;40(25):2863-2866.
doi: 10.1200/JCO.22.00622. Epub 2022 Jun 30.

Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!

Ola Landgren  1 , Dickran Kazandjian  1
Affiliations
Editorial

Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!

Ola Landgren et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dickran Kazandjian

Honoraria: Arcellx, BMS, Sanofi

Speakers' Bureau: Curio Science, Aptitude Health, Cure Educated Patient, Plexus

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Distribution of patients in the current study. In the Myeloma XI trial, 1,248 transplant eligible patients were randomly assigned to lenalidomide (n = 730) or observation (n = 518) at 3 months after HDM-ASCT. A total of 818 patients had HDM-ASCT + 3 bone marrow samples sent to the central laboratory (lenalidomide, n = 495; observation, n = 323). Of the samples received, 750 of 818 (91.7%) were informative for MRD status (lenalidomide n = 452 of 495 [91.9%] and observation n = 298 of 323 [92.3%]). A comparison of those patients with and without informative MRD data showed no significant difference in overall survival or baseline characteristics. ASCT, autologous stem-cell transplantation; HDM-ASCT, high-dose melphalan chemotherapy followed by autologous stem-cell transplantation support; MRD, minimal residual disease.
See this image and copyright information in PMC

Comment on

References

    1. National Cancer Institute (NCI), Surveillance, Epidemiology, and End Results (SEER) Program. 2021. https://seer.cancer.gov/statfacts/html/mulmy.html
    1. Kazandjian D, Landgren O: A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol 43:682-689, 2016 - PMC - PubMed
    1. Landgren O, Hultcrantz M, Diamond B, et al. : Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: The MANHATTAN nonrandomized clinical trial. JAMA Oncol 7:862-868, 2021 - PMC - PubMed
    1. Cavo M, San-Miguel J, Usmani SZ, et al. : Prognostic value of minimal residual disease negativity in myeloma: Combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood 139:835-844, 2022 - PMC - PubMed
    1. Wang J, Arroyo-Suarez R, Dasari S, et al. : Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: A pooled analysis of trials POLLUX, CASTOR and MAIA. Leuk Lymphoma 63:1669-1677, 2022 - PubMed